公开(公告)号：US20050080114A1

公开(公告)日：2005-04-14

申请号：US10935939

申请日：2004-09-08

申请人： Paul Blackler ,  Christine Browne ,  Timothy Coakley ,  Robert Giles ,  Gillian Morrissey

发明人： Paul Blackler ,  Christine Browne ,  Timothy Coakley ,  Robert Giles ,  Gillian Morrissey

IPC分类号： A61K20060101 ,  A61K31/00 ,  A61K31/4439 ,  A61P20060101 ,  A61P3/10 ,  C07D20060101 ,  C07D417/12 ,  C07D417/02

CPC分类号： C07D417/12

摘要： A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterized in that it provides: (i) an infra red spectrum containing peaks at 1763, 912, 856 and 709 cm−1; and/or (ii) a Raman spectrum containing peaks at 1762, 1284, 912 and 888 cm−1; and/or (iii) a solid-state 13C nuclear magnetic resonance spectrum containing peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 138.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53, and 3.46 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

摘要翻译： 5- [4- [2-（N-甲基-N-（2-吡啶基）氨基）乙氧基]苄基]噻唑烷-2,4-二酮，马来酸盐（“多晶型”）的多晶形式，其特征在于 它提供：（i）在1763,912,856和709cm -1处含有峰的红外光谱; 和/或（ii）在1762,1284,912和888cm -1处含有峰的拉曼光谱; 和/或（iii）在111.0,113.6,119.8,129.1,130.9,131.8,134.7,138.7,146.5,152.7,157.5,169.5,171.0,178.7ppm处含有峰的固态13 C核磁共振光谱; 和/或（iv）在5.87,5.30,4.69,4.09,3.88,3.61,3.53和3.46埃处给出计算的晶格间距的X射线粉末衍射（XRPD）图案; 制备这种化合物的方法，含有这种化合物的药物组合物和这种化合物在医药中的用途。